ArticleAnnals of coloproctology2025

Effectiveness of oxaliplatin-based second-line therapy following cetuximab+FOLFIRI or bevacizumab+FOLFIRI in KRAS wild-type metastatic colorectal cancer without primary tumor resection.

Yi-Chia Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.